Global Albumin Market to collect US$ 1200 Mn by 2026, Says

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
54
Global Albumin Market to collect US$ 1200 Mn by 2026, Says TMR

Albany, NY, July 13, 2018 (GLOBE NEWSWIRE) -- Transparency Market Research (TMR) has published a new report titled, “ Albumin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global albumin (as excipient) market was valued at US$ 750 Mn in 2017 and is anticipated to reach US$ 1200 Mn by 2026 at a CAGR of over 5.0% from 2018 to 2026. Grant of regulatory approvals coupled with subsequent launch of albumin based products is the key factor expected to propel the market during the forecast period.

Albumin is a water soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins. These play a vital role in regulating blood volume and act as transporters for molecules such as few hormones, bile salts, and ions. Albumin is commonly used as blood volumizer in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries.

Request to View Sample of Report - https://www.transparencymarketresearch.com/sa...ep_id=3984

However, usage of albumin as multifunctional excipient is increasing due to rise in consumption of albumin for applications such as drug formulation, vaccines, drug discovery, culture medium, stabilizing agent, and diagnostics. Albumin has been widely used as a versatile drug carrier in systems such as albumin fusion protein, albumin-drug nanoparticles, and pro-drugs. It is used as a drug carrier for the treatment of various diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis. It also has the ability to bind to extraordinarily diverse range of molecules, as it provides depository for a wide variety of compounds. These factors make albumin most suitable to be used as an excipient in vaccine and drug production.

High Initial Investment for Plant Setup to Restrict Growth

High cost and expertise required to set up a production plant and stringent regulatory criteria hamper the growth of the global albumin (as excipient) market. Extraction of recombinant human serum albumin and processing incurs significant cost. Additionally, expert staff is required to handle operations, as recombinant technology attracts stringent laws and regulations. Moreover, cost associated with refinement of recombinant albumin to attain high purity is a major concern among the industry players. This acts as a major restraint of the market.

Request PDF Brochure of Report: https://www.transparencymarketresearch.com/sa...ep_id=3984

Recombinant Albumin Product Segment to Grow at a Rapid Pace

Recombinant human serum albumin is an advanced form of HSA, which is produced on large scale through gene sequence modification. Manufacture of rHSA is carried out using vectors. The recombinant albumin segment is anticipated to grow at the highest CAGR of 6.5% during the forecast period from 2018 to 2026. Demand for recombinant proteins is rising across the globe, due to less chance of infections. Recombinant human serum albumin has insignificant immunogenicity in a patient’s body which reduces the chances of antibody formation against it and the drug candidate. rHSA acts as a multifunctional excipient to stabilize the drug product by reducing oxidation, aggregation, and surface adsorption. These features make rHSA a preferred choice as an excipient in drug formulations. Several vaccines are produced using recombinant albumin as an excipient such as MMR, MMRV, and rotavirus vaccine live.

Drug Delivery to be Most Promising Application Segment

The drug delivery segment accounted for 25.0% market share in 2017 and the trend is expected to continue in the near future. Usage of human serum albumin nanoparticles as drug delivery systems with applications in various diseases such as cancer is likely to boost the growth of the segment. The drug delivery sub-segment held leading share of the recombinant albumin segment. Ongoing collaborations between biopharmaceutical companies for recombinant albumin-based drug delivery systems are anticipated to fuel the growth of the segment during the forecast period. For instance, in May 2015, Serendex Pharmaceutical initiated phase I trials of Molgradex, a drug candidate for treating rare pulmonary diseases. The drug candidate uses Novozymes’s Recombumin, a recombinant human albumin for the effective delivery of the biologic to lungs.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sa...ep_id=3984

Pharmaceutical & Biotechnology Industry to be Key End-user

The pharmacy and biotechnology industry segment is expected to dominate the market. The segment was valued at US$ 500 Mn in 2017. Rise in research and developmental activities for development of technologically advanced products and increase in government funding have led the growth of the segment. Recombinant human serum albumin is used in the life sciences industry for a wide range of applications, including component of cell and microbial culture media, blocking agent in blotting, growth supporter in recombinant DNA, and hybridoma technology. This is likely to boost the growth of the segment.

Asia Pacific to Grow at a Rapid Pace

Demand for albumin is high in countries such as India and China. However, uptake of these therapeutics is low due to lack of awareness about these products and their therapeutic uses. Hence, awareness programs conducted by organizations such as PPTA, which include International Plasma Awareness Week, to help increase awareness about plasma donation and the different plasma protein therapies available along with their potential uses are expected to increase the uptake of these therapeutics in treating various conditions. The albumin market in Asia Pacific is projected to witness exponential growth during the forecast period. The region is anticipated to gain market share to capture around 26.0% in terms of revenue by 2026.

Request For Custom Research : https://www.transparencymarketresearch.com/sa...ep_id=3984

CSL Behring LLC, Grifols International, S.A., Inc., and Baxter to Lead Market

The albumin market witnesses moderate competition, as only a few players dominate the market. Key players operating in the market include CSL Behring LLC, Grifols International, S.A., Baxter, and Octapharma AG. New entrants refer to new companies that are interested in manufacturing and developing albumin as an excipient. Existing players have substantially large sales, marketing, financial, manufacturing, and other resources, which could pose a major challenge for new entrants. Additionally, stringent government regulations set by the U.S. FDA to monitor the quality of albumin could pose a barrier for new entrants. Players with strong financial and R&D background are anticipated to survive in this competitive market. Other players in the market include InVitria, Novozyme A/S, Sigma-Aldrich Co., HiMedia Laboratories Pvt. Ltd., Albumin Therapeutics, LLC, Medxbio Pte Ltd., RayBiotech, Inc., and SeraCare Life Sciences etc.

More Trending Reports by Transparency Market Research -

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Mr. Nachiket Ghumare Transparency Market Research State Tower 90 State Street, Suite 700, Albany, NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email : sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com Research Blog: http://theglobalhealthnews.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading